Last reviewed · How we verify
Placebo Upadacitinib
Upadacitinib is a JAK1-selective inhibitor that suppresses inflammatory signaling pathways by blocking Janus kinase 1.
Upadacitinib is a JAK1-selective inhibitor that suppresses inflammatory signaling pathways by blocking Janus kinase 1. Used for Rheumatoid arthritis, Atopic dermatitis, Ulcerative colitis.
At a glance
| Generic name | Placebo Upadacitinib |
|---|---|
| Also known as | Rinvoq, Placebo |
| Sponsor | AbbVie |
| Drug class | JAK1 inhibitor |
| Target | JAK1 (Janus kinase 1) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Upadacitinib selectively inhibits JAK1, a key enzyme in the JAK-STAT signaling pathway that mediates inflammatory cytokine signaling. By blocking JAK1, it reduces the production of pro-inflammatory cytokines and chemokines, thereby suppressing immune-mediated inflammation. This mechanism makes it effective for treating autoimmune and inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Atopic dermatitis
- Ulcerative colitis
- Crohn's disease
Common side effects
- Upper respiratory tract infection
- Headache
- Diarrhea
- Nausea
- Increased cholesterol
- Herpes zoster reactivation
Key clinical trials
- Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study. (PHASE2)
- Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (PHASE3)
- A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (PHASE3)
- A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis (PHASE3)
- Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis (PHASE3)
- Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
- A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Upadacitinib CI brief — competitive landscape report
- Placebo Upadacitinib updates RSS · CI watch RSS
- AbbVie portfolio CI